Q2 2024 Earnings Summary
- Improving U.S. Commercial Performance: The Q&A highlighted sequential growth in U.S. active patient numbers and an increased average revenue per patient driven by improved payer approval rates, suggesting increasing market penetration and recurring benefits going forward.
- Robust Clinical Pipeline and Regulatory Milestones: Management detailed strong progress in multiple clinical programs—including NSCLC and pancreatic cancer—with upcoming trial data and regulatory submissions (e.g., METIS application expected to be finalized in 2024), underscoring potential future label expansions and market opportunities.
- Successful International Expansion: Discussions emphasized strong performance in France—with sequential revenue growth (from $10.5 million in Q1 to $14 million in Q2)—and its role as a blueprint for further market penetration in Europe, indicating scalable international growth.
- Regulatory Uncertainty and Delays: The conversations highlighted potential delays in regulatory approvals for the lung cancer indication—including the impact of the new MDR process in Europe and pending METIS submissions—which could postpone commercialization timelines.
- Slow Enrollment in Clinical Trials: Concerns were raised over the slow enrollment in the KEYNOTE-B36 trial, suggesting potential challenges for timely enrollment in the pivotal LUNAR‑2 trial, which may delay key milestones.
- Reliance on Non‑Recurring Revenue Benefits: The quarter’s net revenue benefited from one‑time adjustments (approximately $8 million) that are not expected to recur. This raises concerns over the sustainability of future revenue growth if such benefits diminish.
-
U.S. Pricing & Patients
Q: Are active patient growth and U.S. net pricing sustainable?
A: Management highlighted that active patient numbers have returned to sequential growth and noted a 200 basis point year-over-year improvement in U.S. net selling price—improvements they view as sustainable once non‐recurring benefits are removed. -
Funding Strategy
Q: Will financing enable timely convert paydown this year?
A: They expressed confidence that the multi-tranche financing provides enough cash to pay down the convert, ensuring no anticipated challenges on that front. -
METIS Submission Timeline
Q: When will you finalize the METIS submission?
A: Management’s intent is to finalize the METIS submission this year, with plans to submit soon in both the U.S. and Europe. -
CE Mark & METIS Path
Q: What’s the timeline for CE Mark and METIS update?
A: They clarified that a late second-half target for CE Mark was not stated and are actively finalizing their next steps for the METIS submission. -
France Market Performance
Q: How did France revenue compare Q1 vs Q2 and outlook?
A: France revenue increased from about $10.5 million in Q1 to $14 million in Q2, and management sees this market as growing steadily alongside improved U.S. reimbursement rates. -
LUNAR Regulatory Process
Q: What is the regulatory outlook for LUNAR in Europe and the U.S.?
A: The U.S. timeline remains unchanged with no panel expected, while in Europe the new MDR process has pushed the decision to the second half—though discussions with the notified body (TUV Rheinland) remain constructive. -
KEYNOTE-B36 & LUNAR-2
Q: Does B36 data affect confidence in LUNAR-2?
A: They stressed that B36 is a distinct Phase II trial and does not diminish their confidence in the Phase III LUNAR-2 program, maintaining a separate approach for the U.S. market. -
Reimbursement Stability
Q: Are there risks to future reimbursement rates in France?
A: Management noted that, unlike the U.S. and Germany, France operates under a national reimbursement model that should keep revenue stable, with no expected future rate drops. -
Clinician Feedback on METIS
Q: What are clinicians saying about METIS results?
A: Feedback from METIS at ASCO indicated strong interest across oncology disciplines, with clinicians valuing the delay in progression as a meaningful endpoint for patients. -
France Market Sizing
Q: How does the France market size compare to prior fiscal years?
A: Management did not break out fiscal '23 figures for France but expects it to be a Germany-like market opportunity, significant enough for major revenue contributions. -
Pancreatic Cancer Staging
Q: What proportion of pancreatic cases are locally advanced?
A: They explained that about 10% of patients are operable, with roughly 35–40% diagnosed as locally advanced—forming the target group for PANOVA-3. -
B36 Enrollment Impact
Q: How is slow B36 enrollment affecting LUNAR-2?
A: The slow enrollment in B36, a Phase II trial running in a smaller patient group, is not expected to impact LUNAR-2, which is targeting a much larger portion of U.S. patients. -
Pancreatic Opportunity
Q: How does pancreatic cancer response compare to other indications?
A: Early insights suggest that early use of TTFields in locally advanced pancreatic cancer is promising, aligned with the notion that earlier treatment yields better outcomes. -
Enrollment Criteria Clarification
Q: What are the enrollment criteria for recent trials?
A: Management confirmed that trials are enrolling patients with locally advanced disease in the 35–40% range, underscoring a clear patient selection strategy.